Skip to main content
SpringerLink
Log in

Pharmacological Approaches to Reduce Perioperative Transfusion Requirements in the Aged

  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Although iron deficiency is undoubtedly the commonest cause of anaemia even in elderly people, the aetiology is not always clear owing to various underlying diseases. Correction of anaemia is sometimes needed before surgery. The use of drugs that may influence blood coagulation, such as aspirin (acetylsalicylic acid), should be checked. Perioperative allogenic blood transfusion can often be avoided by the use of autologous blood and improved surgical techniques. Autologous blood donations are preferable in cases of planned surgery. Epoetin (recombinant human erythropoietin) in combination with iron supplementation facilitates the donation of autologous blood, even in elderly patients.

Another method of avoiding allogenic blood transfusion is the collection and reuse of the blood a patient sheds in operations. During and/or after surgery, many haemostatic agents are available. Moreover, recent developments in gene engineering have enabled the utilisation of recombinant cytokines and coagulation factors. Further work remains to be done to define the proper use of these agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cumming PD, Wallace EL, Schorr JB, et al. Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody-negative. N Engl J Med 1989; 321: 914–6

    Google Scholar 

  2. Alter HJ, Purcell RH, Shin JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A,non-B hepatitis. N Engl J Med 1989; 321: 1494–500

    PubMed  CAS  Google Scholar 

  3. Inaba S, Sato H, Okochi K, et al. Prevention of transmission of human T-lymphotropic virus type 1 (HTLV-1) through transfusion, by donor screening with antibody to the virus, one-year experience. Transfusion 1989; 29: 7–11

    PubMed  CAS  Google Scholar 

  4. McLeod BC. Immunologic factors in reactions to blood transfusions. Heart Lung 1980; 9: 675–81

    PubMed  CAS  Google Scholar 

  5. Anderson KC, Weinstein HJ. Transfusion-associated graftversus host disease. N Engl J Med 1990; 323: 315–21

    PubMed  CAS  Google Scholar 

  6. Schriemer PA, Longnecker DE, Mintz PD. The possible immunosuppressive effects of perioperative blood transfusion in cancer patients. Anesthesiology 1988; 68: 422–8

    PubMed  CAS  Google Scholar 

  7. Wasman J, Goodnough LT. Autologous blood donation for elective surgery: effect on physician transfusion behavior. JAMA 1987; 258: 3135–7

    PubMed  CAS  Google Scholar 

  8. Beris P, Mermillod B, Levy G, et al. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. Vox Sang 1993; 65: 212–8

    PubMed  CAS  Google Scholar 

  9. Canadian Orthopedic Perioperative Erythropoietin Study Group. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet 1993; 341: 1227–32

    Google Scholar 

  10. Mercuriali F, Zanella A, Barosi G, et al. Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion 1993; 33: 55–60

    PubMed  CAS  Google Scholar 

  11. Tasaki T, Ohto H, Hashimoto C, et al. Recombinant human erythropoietin for autologous blood donation: effects on perioperative red-blood-cell and serum erythropoietin production. Lancet 1992; 339: 773–5

    PubMed  CAS  Google Scholar 

  12. McLennan WJ, Andrews GR, Macleod C, et al. Anemia in the elderly. Q J Med 1973; 42: 1–13

    PubMed  CAS  Google Scholar 

  13. Lipschitz DA, Udupa KB, Milton KY, et al. Effect of age on hematopoiesis in man. Blood 1984; 63: 502–9

    PubMed  CAS  Google Scholar 

  14. Tanaka Y, Inoue T. Fatty marrow in the vertebrae: a parameter for hematopoietic activity in the aged. J Gerontol 1976; 31: 527–32

    PubMed  CAS  Google Scholar 

  15. Carpenter MA, Kendall RG, O’Brien AE, et al. Reduced erythropoietin response to anaemia in elderly patients with normocytic anaemia. Eur J Haematol 1992; 49: 119–21

    PubMed  CAS  Google Scholar 

  16. Casale G, Bonora C, Migliavacca A, et al. Serum ferritin and ageing. Age Ageing 1981; 10: 119–22

    PubMed  CAS  Google Scholar 

  17. Evans DMD. Haematological aspects of iron deficiency in the elderly. Geront Clin 1971; 13: 12–30

    PubMed  CAS  Google Scholar 

  18. Schuster SJ, Caro J. Erythropoietin: physiologic basis for clinical applications. Vox Sang 1993; 65: 169–79

    PubMed  CAS  Google Scholar 

  19. Tasaki T, Ohto H, Noguchi M, et al. Iron and erythropoietin measurement in autologous blood donors with anemia: implications for management. Transfusion 1994; 34: 337–43

    PubMed  CAS  Google Scholar 

  20. Mori M, Murai Y, Hirai M, et al. Serum erythropoietin titers in the aged. Mech Ageing Dev 1988; 46: 105–9

    PubMed  CAS  Google Scholar 

  21. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322: 1689–92

    PubMed  CAS  Google Scholar 

  22. Baer AN, Dessypris EN, Goldwasser E, et al. Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol 1987; 66: 559–64

    PubMed  CAS  Google Scholar 

  23. Coleman DH, Stevens AR, Finch CA. The treatment of iron deficiency anemia. Blood 1955; 10: 567–81

    PubMed  CAS  Google Scholar 

  24. Winearls CG, Oliver DO, Pippard MJ, et al. Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis. Lancet 1986; 2: 1175–8

    PubMed  CAS  Google Scholar 

  25. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and clinical trial. N Engl J Med 1987; 316: 73–8

    PubMed  CAS  Google Scholar 

  26. Adamson JW. The promise of recombinant human erythropoietin. Semin Hematol 1989; 26: 5–8

    PubMed  CAS  Google Scholar 

  27. MacDougall IC, Lewis NP, Saunders MJ, et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990; 335: 489–93

    PubMed  CAS  Google Scholar 

  28. Oster W, Herrmann F, Gamm H, et al. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 1990; 8: 956–62

    PubMed  CAS  Google Scholar 

  29. Matsumoto T, Endoh K, Kamisango K, et al. Effect of recombinant human erythropoietin on anticancer drug-induced anaemia. Br J Haematol 1900; 75: 463–8

    Google Scholar 

  30. Davis HP. Erythropoietin for patient refusing blood transfusion. Lancet 1990; 336: 384

    PubMed  CAS  Google Scholar 

  31. Pincus T, Olsen NJ, Russell I, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990; 89: 161–8

    PubMed  CAS  Google Scholar 

  32. Eschbach JW, Kelly MR, Haley NR, et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321: 158–63

    PubMed  CAS  Google Scholar 

  33. de Vries EGE, Biesma B, Willemse P, et al. Efficacy, tolerability, and pharmacokinetics of rhIL-3 for patients(pts) with ovarian carcinomas(oc) treated with chemotherapy(ct) [abstract]. Proc Am Soc Clin Oncol 1991; 10: 640a

    Google Scholar 

  34. Bretti S, Kamthan A, Hicks F, et al. Phase I study of sequential IL-3 and GM-CSF by continuous intravenous infusion [abstract]. Proc Am Soc Clin Oncol 1992; 11: 537

    Google Scholar 

  35. Goldman S, Copeland J, Moritz T, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 1988; 77: 1324–32

    PubMed  CAS  Google Scholar 

  36. Michelson EL, Morganroth J, Torosian M, et al. Relation of preoperative use of aspirin to increased mediastinal blood loss after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 1978; 78: 694–7

    Google Scholar 

  37. Giordano GF, Dockery J, Wallace BA, et al. An autologous blood program coordinated by a regional blood center: a 5-year experience. Transfusion 1991; 31: 509–12

    PubMed  CAS  Google Scholar 

  38. Zuck TF, Carey PM. Autologous transfusion pratice. Vox Sang 1990; 58: 234–53

    PubMed  CAS  Google Scholar 

  39. Tasaki T, Ohto H, Abe R, et al. New ‘Leap-Frog’ technique for autologous blood donation. Transfus Sci 1991; 12: 307–10

    PubMed  CAS  Google Scholar 

  40. Tasaki T, Ohto H, Noguchi M, et al. Autologous blood donation: elective surgery in children. Vox Sang 1994; 66: 188–93

    PubMed  CAS  Google Scholar 

  41. Santoli E. Safety of preoperative blood donation (for auto-transfusion) for cardiac surgery patients. Transfusion 1993; 33: 91

    PubMed  CAS  Google Scholar 

  42. AuBuchon JP, Popovsky MA. The safety of preoperative autologous blood donation in the nonhospital setting. Transfusion 1991; 31: 513–7

    PubMed  CAS  Google Scholar 

  43. Biesma DH, Kraaijenhagen RJ, Poortman J, et al. The effect of oral iron supplementation on erythropoiesis in autologous blood donors. Transfusion 1992; 32: 162–5

    PubMed  CAS  Google Scholar 

  44. Miller ME, Cronkite EP, Garcia JF. Plasma levels of immunoreactive erythropoietin after acute blood loss in man. Br J Haematol 1982; 52: 545–9

    PubMed  CAS  Google Scholar 

  45. Walker RH, editor. Technical manual. Arlington: American Association of Blood Banks, 1990

    Google Scholar 

  46. Lorentz A, Jendrissek A, Eckardt KU, et al. Serial immunoreactive erythropoietin levels in autologous blood donors. Transfusion 1991; 31: 650–4

    PubMed  CAS  Google Scholar 

  47. Kickler TS, Spivak JL. Effect of repeated whole blood donations on serum immunoreactive erythropoietin levels in autologous donors. JAMA 1988; 260: 65–7

    PubMed  CAS  Google Scholar 

  48. Kruskall MS, Glazer EE, Leonard SS, et al. Utilization and effectiveness of a hospital autologous preoperative blood donor program. Transfusion 1986; 26: 335–40

    PubMed  CAS  Google Scholar 

  49. Miyake T, Kung CKH, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252: 5558–64

    PubMed  CAS  Google Scholar 

  50. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985; 313: 806–10

    PubMed  CAS  Google Scholar 

  51. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985; 82: 7580–4

    PubMed  CAS  Google Scholar 

  52. McMahon FG, Vargas R, Ryan M, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990; 76: 1718–22

    PubMed  CAS  Google Scholar 

  53. Tasaki T, Ohto H, Noguchi M, et al. Administration of recombinant human erythropoietin for preoperative autologous blood donation: intravenously or subcutaneously. Transfusion 1993; 33 Suppl.: S105

    Google Scholar 

  54. MacDougall IC, Roberts DE, Neubert GA, et al. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989; 1: 425–7

    PubMed  CAS  Google Scholar 

  55. Christensen RD, Koenig JM, Viskochil DH, et al. Downmodulation of neutrophil production by erythropoietin in human hematopoietic clones. Blood 1989; 74: 817–22

    PubMed  CAS  Google Scholar 

  56. Goodnough LT, Price TH, Pavin CA, et al. Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy. Br J Haematol 1994; 87: 695–9

    PubMed  CAS  Google Scholar 

  57. Biesma DH, Kraaijenhagen RJ, Marx JJM, et al. The efficacy of subcutaneous recombinant human erythropoietin in the correction of phlebotomy-induced anaemia in autologous blood donors. Transfusion 1993; 33: 825–9

    PubMed  CAS  Google Scholar 

  58. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992–1000

    PubMed  CAS  Google Scholar 

  59. Evans RW, Rader B, Manninen DL, Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990; 263: 825–30

    PubMed  CAS  Google Scholar 

  60. Taylor JE, Henderson IS, Stewart WK, et al. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. Lancet 1991; 338: 1361–2

    PubMed  CAS  Google Scholar 

  61. Marquet RL, Van Papendrecht MAH, Bush OR, et al. Blood donation leads to a decrease in natural killer cell activity: a study in normal blood donors and cancer patients. Transfusion 1993; 33: 368–73

    PubMed  CAS  Google Scholar 

  62. Van Papendrecht MAWH, Marquet RL, Jeekel J. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993; 328: 137–26

    Google Scholar 

  63. Consensus Conference. Perioperative red blood cell transfusion. JAMA 1988; 260: 2700–3

    Google Scholar 

  64. Surgenor DM, Wallace EL, Churchill WH, et al. Red cell transfusions in total knee and total hip replacement surgery. Transfusion 1991; 31: 531–7

    PubMed  CAS  Google Scholar 

  65. Salem-Schatz SR, Avorn J, Soumerai SB. Influence of clinical knowledge, organizational context, and practice style on transfusion decision making: implications for practice change strategies. JAMA 1990; 264: 476–83

    PubMed  CAS  Google Scholar 

  66. Heiss MM, Mempel W, Jauch KW, et al. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet 1993; 342: 1328–33

    PubMed  CAS  Google Scholar 

  67. Fernandez MC, Gottlieb M, Menitove JE. Blood transfusion and postoperative infection in orthopedic patients. Transfusion 1992; 32: 318–22

    PubMed  CAS  Google Scholar 

  68. Murphy MF, Brozovic B, Murphy W, et al. Guidelines for platelet transfusions. Transfus Med 1992; 2: 311–8

    PubMed  CAS  Google Scholar 

  69. Suzuki K, Akiyama H, Takamoto S, et al. Transfusion-associated graft-versus-host disease in a presumably immunocompetent patient after transfusion of stored packed red cells. Transfusion 1992; 32: 358–60

    PubMed  CAS  Google Scholar 

  70. Ness PM, Bourke DL, Walsh PC. A randomized trial of perioperative hemodilution versus transfusion of preoperatively deposited autologous blood in elective surgery. Transfusion 1991; 31: 226–30

    Google Scholar 

  71. Trouwborst A, Van Woerkens ECSM, Van Daele M, et al. Acute hypervolaemic haemodilution to avoid blood transfusion during major surgery. Lancet 1990; 336: 1295–7

    PubMed  CAS  Google Scholar 

  72. Garcia-Rinaldi R, Simmons P, Salcedo V, et al. A technique for spot application of fibrin glue during open heart operations. Ann Thorac Sury 1989; 47: 59–61

    CAS  Google Scholar 

  73. Dresdale A, Bowman FO, Malm JR, et al. Hemostatic effectiveness of fibrin glue derived from single-donor fresh frozen plasma. Ann Thorac Surg 1985; 40: 385–7

    PubMed  CAS  Google Scholar 

  74. Lupinetti FM, Stoney WS, Alford WC, et al. Cryoprecipitatetopical thrombin glue: initial experience in patients undergoing cardiac operations. J Thorac Cardiovasc Surg 1985; 90: 502–5

    PubMed  CAS  Google Scholar 

  75. Languino LR, Plescia J, Duperray A, et al. Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell 1993; 73: 1423–34

    PubMed  CAS  Google Scholar 

  76. Kjaergard HK, Weis-Fogh VS, Thiis JJ. Preparation of autologous fibrin glue from pericardial blood. Ann Thorac Surg 1993; 55: 543–4

    PubMed  CAS  Google Scholar 

  77. Park MS, Cha C. Biochemical aspects of autologous fibrin glue derived from ammonium sulfate precipitation. Laryngoscope 1993; 103: 193–6

    PubMed  CAS  Google Scholar 

  78. Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308: 8–12

    PubMed  CAS  Google Scholar 

  79. Salzman EW, Weinstein MJ, Weintraub RM, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. N Engl J Med 1986; 314: 1402–6

    PubMed  CAS  Google Scholar 

  80. Ansell J, Klassen V, Low R, et al. Does desmopressin acetate prophylaxis reduce blood loss after valvular heart operations? A randomized, double-blind study. J Thorac Cardiovasc Surg 1992; 104: 117–23

    PubMed  CAS  Google Scholar 

  81. Shepherd LL, Hutchinson RJ, Worden EK, et al. Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis. J Pediatr 1989; 114: 470–2

    PubMed  CAS  Google Scholar 

  82. Westaby S. Aprotinin in perspective. Ann Thorac Surg 1993; 55: 1033–41

    PubMed  CAS  Google Scholar 

  83. Bidstrup BP, Harrison J, Royston D, et al. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993; 55: 971–6

    PubMed  CAS  Google Scholar 

  84. Dietrich W, Spannagl M, Jochum M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 1990; 73: 1119–26

    PubMed  CAS  Google Scholar 

  85. Havel M, Tenfelsbauer H, Knobl P, et al. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg 1991; 101: 968–72

    PubMed  CAS  Google Scholar 

  86. Cosgrove DM, Fleric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Sury 1992; 54: 1031–8

    Google Scholar 

  87. Bidstrup BP, Underwood SR, Sapsford RN, et al. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993; 105: 147–53

    PubMed  CAS  Google Scholar 

  88. Himmelreich G, Muser M, Neuhaus P, et al. Different aprotinin applications influencing hemostatic changes in orthotopic liver transplantation. Transplantation 1992; 53: 132–6

    PubMed  CAS  Google Scholar 

  89. Vander Salm TJ, Ansell JE, Okike ON, et al. The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: a double-blind randomized study. J Thorac Cardiovasc Surg 1988; 95: 538–40

    PubMed  CAS  Google Scholar 

  90. Horrow JC, Hlavacek J, Strong MD, et al. Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Sury 1990; 99: 70–4

    CAS  Google Scholar 

  91. Gralnick HR, Greipp P. Thrombosis with epsilon aminocaproic acid therapy. Am J Clin Pathol 1971; 56: 151–4

    PubMed  CAS  Google Scholar 

  92. Fish KJ, Sarnquist FH, Van Steennis C, et al. A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations. J Thorac Cardiovasc Surg 1986; 91: 436–42

    PubMed  CAS  Google Scholar 

  93. Walker ID, Davidson JF, Faichney A, et al. A double blind study of prostacyclin in cardiopulmonary bypass surgery. Br J Haematol 1981; 49: 415–23

    PubMed  CAS  Google Scholar 

  94. Gomperts E, Lawrence J, Liu SL, et al. Safety and efficacy studies of recombinant tissue factor [abstract]. Thromb Haemost 1991; 65: 677

    Google Scholar 

  95. Schmidt ML, Smith HE, Gamerman S, et al. Prolonged recombinant activated factor VII (rF VIIa) treatment for severe bleeding in a factor-IX-deficient patient with an inhibitor. Br J Haem 1991; 78: 460–63

    CAS  Google Scholar 

  96. Philip M, Faris PM, Ritter MA, et al. Unwashed filtered sled blood collected after knee and hip arthroplasties. J Bone Joint Surg Am 1991; 73A: 1169–78

    Google Scholar 

  97. Hauer JM, Thurer RL. Controversies in autotransfusion. Vox Sang 1984; 46: 8–12

    PubMed  CAS  Google Scholar 

  98. Tector AJ, Dressier DK, Glassner-Davis RM. A new method of autotransfusing blood drained after cardiac surgery. Ann Thorac Surg 1985; 40: 305–7

    PubMed  CAS  Google Scholar 

  99. Yaw PB, Sentany M, Wink WJ, et al. Tumor cells carried through autotransfusion. JAMA 1975; 231: 490–1

    PubMed  CAS  Google Scholar 

  100. Cosgrove DM, Amiot DM, Meserko JJ. An improved technique for autotransfusion of shed mediastinal blood. Ann Thorac Surg 1985; 40: 519–20

    PubMed  CAS  Google Scholar 

  101. Zauber NP, Zauber AG, Gordon FJ, et al. Iron supplementation after femoral head replacement for patients with normal iron stores. JAMA 1992; 267: 525–7

    PubMed  CAS  Google Scholar 

  102. Spivak JL, Hocans BB. Clinical evaluation of a radioimmunoassay (RIA) for serum erythropoietin (EPO) using reagents derived from recombinant erythropoietin (rEPO). Blood 1987; 70 (Suppl.1): 426

    Google Scholar 

  103. Levine E, Rosen A, Sehgal L, et al. Accelerated erythropoiesis: the hidden benefit of autologous donation. Transfusion 1990; 30: 295–7

    PubMed  CAS  Google Scholar 

  104. Goldman S, Copeland J, Moritz T, et al. Improvement in graft patency without bleeding complications by postoperative initiation of aspirin therapy after coronary artery bypass grafting [abstract]. Thromb Haemostas 1989; 62: 33a

    Google Scholar 

  105. Gordon MS, Hoffman R. Growth factors affecting human thrombocytopoiesis: potential agents for the treatment of thrombocytopenia. Blood 1992; 80: 302–7

    PubMed  CAS  Google Scholar 

  106. Ravoet C, Piccart MJ, Bron D, et al. A phase I clinical trial of recombinant human interleukin-6 (rhIL-6) in solid tumors [abstract]. Proc Am Assoc Cancer Res 1992; 33: 1389

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Blood Transfusion Service, Fukushima Medical College, Hikariga-oka, Fukushima City, Fukushima, 960-12, Japan

    Tetsunori Tasaki & Hitoshi Ohto

  2. Department of Surgery, Fukushima Medical College, Fukushima City, Fukushima, Japan

    Ryoichi Motoki

Authors
  1. Tetsunori Tasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hitoshi Ohto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryoichi Motoki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tasaki, T., Ohto, H. & Motoki, R. Pharmacological Approaches to Reduce Perioperative Transfusion Requirements in the Aged. Drugs & Aging 6, 91–104 (1995). https://doi.org/10.2165/00002512-199506020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199506020-00002

Keywords

Search

Navigation